Benchmark Initiates Coverage On DPCM Capital with Buy Rating, Announces Price Target of $14
Benchmark analyst David Williams initiates coverage on DPCM Capital (NYSE:XPOA) with a Buy rating and announces Price Target of $14.
Chardan Capital Initiates Coverage On Immuneering with Buy Rating, Announces Price Target of $18
Chardan Capital analyst Geulah Livshits initiates coverage on Immuneering (NASDAQ:IMRX) with a Buy rating and announces Price Target of $18.
HC Wainwright & Co. Downgrades Meridian Bioscience to Neutral, Raises Price Target to $34
HC Wainwright & Co. analyst Yi Chen downgrades Meridian Bioscience (NASDAQ:VIVO) from Buy to Neutral and raises the price target from $30 to $34.
HC Wainwright & Co. Maintains Buy on NextPlay Technologies, Lowers Price Target to $1
HC Wainwright & Co. analyst Scott Buck maintains NextPlay Technologies (NASDAQ:NXTP) with a Buy and lowers the price target from $2 to $1.
Needham Maintains Buy on Intercept Pharmaceuticals, Lowers Price Target to $22
Needham analyst Joseph Stringer maintains Intercept Pharmaceuticals (NASDAQ:ICPT) with a Buy and lowers the price target from $25 to $22.
Keybanc Maintains Overweight on Materion, Lowers Price Target to $100
Keybanc analyst Philip Gibbs maintains Materion (NYSE:MTRN) with a Overweight and lowers the price target from $106 to $100.
Keybanc Maintains Overweight on Aspen Technology, Raises Price Target to $210
Keybanc analyst Jason Celino maintains Aspen Technology (NASDAQ:AZPN) with a Overweight and raises the price target from $175 to $210.
Benchmark Initiates Coverage On NOW with Buy Rating, Announces Price Target of $13
Benchmark analyst Douglas Becker initiates coverage on NOW (NYSE:DNOW) with a Buy rating and announces Price Target of $13.
Oppenheimer Initiates Coverage On Blueprint Medicines with Outperform Rating, Announces Price Target of $80
Oppenheimer analyst Matthew Biegler initiates coverage on Blueprint Medicines (NASDAQ:BPMC) with a Outperform rating and announces Price Target of $80.
Wedbush Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $3
Wedbush analyst Robert Driscoll initiates coverage on Aprea Therapeutics (NASDAQ:APRE) with a Outperform rating and announces Price Target of $3.